Funding for this research was provided by:
National Heart, Lung, and Blood Institute (#2R01-HL111821)
Received: 7 February 2020
Accepted: 14 March 2020
First Online: 16 April 2020
Change Date: 4 May 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: The trial was approved on 4/26/17 by Partners Health Care System’s Human Subjects Committee (protocol # 2017P000774/PHS) as the central IRB. It was also approved by the University of Pittsburgh Institutional Review Board (#EXT17120148) on 12/21/17, and by the Vanderbilt University Institutional Review Board (#171464) on 10/19/17. Informed consent will be obtained from all study participants.
: Not applicable.
: NR has received royalties from UpToDate, Inc., for writing on smoking cessation topics and consulting fees from Achieve Life Sciences for development of cytisine, an investigational smoking cessation medication. She has consulted with Pfizer, Inc., the manufacturer of Chantix (varenicline) smoking cessation medication, without accepting fees.DS has consulted for Pfizer regarding anticoagulation but not regarding smoking cessation.HAT has consulted for Achieve Life Sciences on a phase III clinical trial for cytisine. HAT is a multiple PI on a cessation study of non-daily smokers (PI: Primack; 5 R01 DA034629 04) for which the active study medication (nicotine gum) was donated by the manufacturer. HAT is the project lead for a Cancer Center Support Grant Supplement (PI: Pietenpol; 3 P30 CA068485 22S3) for which Chantix (varenicline) was donated by the manufacturer. HAT has not received funds from Achieve Life Sciences, nor the drug manufacturers.These authors have no competing interests to declare: KS, AD, KG, ED, AN, JK, DEL, SR, YC.